GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer
February 23 2021 - 9:00AM
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion
of Eric Feldman, M.D., to Senior Vice President and Chief Medical
Officer. Dr. Feldman joined the Company in 2019 and was previously
Vice President, Global Clinical Development.
“Eric is internationally recognized for his work in the
development of new therapies for the treatment of leukemias and
related bone marrow disorders, and in the past two years, has
established himself as a leader in our management group as well as
in the trenches with our clinical operations team. Having spent his
career dedicated to patients with hematologic malignancies, he is
especially well positioned to lead our uproleselan program as it
advances through Phase 3 clinical trials. In addition, his
extensive clinical research background will serve us well as we
drive forward other programs in our pipeline,” said Rachel King,
Chief Executive Officer.
Before joining GlycoMimetics, Dr. Feldman served as Chief
Medical Officer at Amphivena Therapeutics, Inc., focusing on
breakthrough blood cancer treatments and T-cell engagement
technologies, and prior to that, he oversaw the myeloid leukemia
antibody-drug conjugate (ADC) program at Seattle Genetics, Inc. He
has led or participated in the conduct of numerous clinical trials,
several leading to U.S. Food and Drug Administration (FDA)
approval. Dr. Feldman’s extensive academic career includes a recent
position as Professor of Medicine and Director of the Hematological
Malignancies Service at Weill-Cornell/New York Presbyterian
Hospital, as well as faculty positions at New York Medical College
and the University of Texas, MD Anderson Cancer Center. Dr. Feldman
has authored over 150 scientific articles and is a former Editor-in
Chief of the journal Leukemia Research. He earned his medical
degree at New York Medical College and holds a B.A. from Tulane
University.
Separately, Dr. Helen Thackray, M.D. F.A.A.P., has decided to
leave the company to pursue another opportunity. She joined the
company 15 years ago, and most recently served as Senior Vice
President, Clinical Development and Chief Medical Officer.
“Helen’s contributions to the Company have been invaluable,
leading two programs to late-stage development, and creating
important relationships with clinicians all over the world. We are
grateful for her years of service to GlycoMimetics and wish her
well in her next endeavor,” said Ms. King.
About Uproleselan (GMI-1271)
Discovered and developed by GlycoMimetics, uproleselan is an
investigational, first-in-class, targeted inhibitor of E-selectin.
Uproleselan (yoo’ pro le’ sel an), currently in a comprehensive
Phase 3 development program in AML, has received Breakthrough
Therapy designation from the U.S. FDA and from the Chinese
regulatory authority for the treatment of adult AML patients with
relapsed or refractory disease. Uproleselan is designed to block
E-selectin (an adhesion molecule on cells in the bone marrow) from
binding with blood cancer cells as a targeted approach to
disrupting well-established mechanisms of leukemic cell resistance
within the bone marrow microenvironment. In a Phase 1/2 clinical
trial, uproleselan was evaluated in both newly diagnosed elderly
and relapsed or refractory patients with AML. In both populations,
patients treated with uproleselan together with standard
chemotherapy achieved better-than-expected remission rates and
overall survival compared to historical controls, which have been
derived from results from third-party clinical trials evaluating
standard chemotherapy, as well as lower-than-expected
induction-related mortality rates. Treatment in these patient
populations was generally well-tolerated, with fewer than expected
adverse effects.
About GlycoMimetics, Inc.
GlycoMimetics is a biotechnology company with a focus in
hematology-oncology and a pipeline of novel glycomimetic drugs, all
designed to address unmet medical needs resulting from diseases in
which carbohydrate biology plays a key role. GlycoMimetics' drug
candidate, uproleselan, an E-selectin antagonist, was evaluated in
a Phase 1/2 clinical trial as a potential treatment for AML and is
being evaluated across a range of patient populations including in
a Company-sponsored Phase 3 trial in relapsed/refractory AML under
Breakthrough Therapy Designation. Rivipansel, a pan-selectin
antagonist, is being explored for use in treatment of acute VOC in
sickle cell disease. GlycoMimetics has also completed a Phase 1
clinical trial with another wholly-owned drug candidate, GMI-1359,
a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn
more at www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements. These
forward-looking statements include those relating to the potential
benefits and impact of the Company’s drug candidates. Actual
results may differ materially from those described in these
forward-looking statements. For a further description of the risks
associated with these statements, as well as other risks facing
GlycoMimetics, please see the risk factors described in the
Company’s annual report on Form 10-K filed with the U.S. Securities
and Exchange Commission (SEC) on February 28, 2020, its quarterly
report on Form 10-Q filed with the SEC on November 6, 2020, and
other filings GlycoMimetics makes with the SEC from time to time.
Forward-looking statements speak only as of the date of this
release, and GlycoMimetics undertakes no obligation to update or
revise these statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210223005673/en/
Investor Contact: Shari Annes Phone: 650-888-0902
Email: sannes@annesassociates.com
Media Contact: Jamie Lacey-Moreira Phone: 410-299-3310
Email: jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024